| Literature DB >> 33489746 |
Young Jin Lee1, In Beom Jeong1.
Abstract
Hydrogen Fluoride (HF) inhalation is one of the industrial accidents. It causes serious damage, although it is quickly recognized. Since hydrofluoric acid leaks are under surveillance by the alarm system, and low concentrations of gas also have a distinctive smell, most accidents occur from exposure in a short period to a large amount of HF. Thus, prolonged exposure to HF is exceedingly rare in a developed country. We report seven cases of chemical pneumonitis due to HF inhalation to share clinical course and prognosis.Entities:
Keywords: Chemical pneumonitis; Hydrogen fluoride; Inhalation
Year: 2020 PMID: 33489746 PMCID: PMC7804834 DOI: 10.1016/j.rmcr.2020.101338
Source DB: PubMed Journal: Respir Med Case Rep ISSN: 2213-0071
Fig. 1A 49-year-old man (case 1). Diffuse patchy ground-glass opacities in both lungs of hydrogen fluoride-induced pneumonitis.
The symptoms and test results of the cases at presentation.
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | Case 7 | |||
|---|---|---|---|---|---|---|---|---|---|
| Age | 48 | 61 | 50 | 45 | 57 | 61 | 55 | ||
| Sex | male | male | male | male | male | male | male | ||
| past medical history | no | HTN 5yr dyslipidemia 5 yr | no | no | HTN 15yr dyslipidemia 1yr | DM | HCV early LC child A | ||
| ex-smoker | |||||||||
| Symptoms & Sign | fever/chilling | 100% | + | + | + | + | + | + | + |
| myalgia | 100% | + | + | + | + | + | + | + | |
| dyspnea | 100% | mMRC4 | mMRC4 | MRC2 | mMRC2 | mMRC4 | mMRC3 | MMRC3 | |
| Skin | 57% | redness | redness | pruritus, desquamation | desquamation | ||||
| desquamation | pruritus | ||||||||
| headache | 100% | + | + | + | + | + | + | ||
| insomnia | 57% | + | + | + | + | ||||
| sore throat | 71% | + | + | + | + | + | |||
| voice change | 43% | + | + | + | |||||
| runny nose | 29% | + | + | ||||||
| cough | 57% | + | + | + | + | ||||
| sputum | 43% | + | + | + | |||||
| lung sound | 29% | decreased | decreased | ||||||
| laboratory findings | WBC | 15.6 | 11.4 | 8.2 | 6.1 | 14.60 | 11.50 | 8.9 | |
| Hemoglobin | 14.8 | 15.6 | 13.4 | 14.4 | 10.8 | 14.0 | 15.9 | ||
| Platelet | 312 | 331 | 332 | 224 | 354 | 193 | 114 | ||
| CRP | 12 | 3.3 | 6.6 | 10.9 | 0.1 | ||||
| Calcium | 8.69 | 8.5 | 8.9 | 8.4 | 9.1 | 8.9 | |||
| Phosphate | 1.71 | 4.2 | 3.4 | 3.31 | 3.7 | 2.6 | |||
| ESR | 43 | 33 | 58 | 60 | 11 | ||||
| BNP | 41 | 395.4 | |||||||
| procalcitonin | <0.02 | 0.291 | |||||||
| Creatinine | 0.91 | 0.81 | 0.82 | 1.01 | 0.84 | 1.18 | 0.86 | ||
| Radiologic findings | Chest X-ray | 14% | no active lesion | no active lesion | no active lesion | patchy GGO | no active lesion | no active lesion | |
| CT GGO | 100% | diffuse patchy | diffuse patchy | patchy | diffuse patchy | diffuse patchy | diffuse patchy | patchy | |
| CT nodules | 43% | centrilobular nodules | centrilobular nodules | centrilobular nodules | |||||
| affected lung lobes | entire lung | both upper lungs | entire lung | entire lung | entire lung | entire lung | both upper lungs | ||
| other findings | subsegmental atelectasis both lower lung | subpleural nodule right lower lung | subsegmental atelectasis | ||||||
| both lower lung | |||||||||
| pulmonary function test | FVC, % | 89 | 101 | 104 | 110 | 91 | 92 | 87 | |
| FEV1, % | 96 | 88 | 106 | 106 | 102 | 97 | 98 | ||
| FEV1/FVC, % | 81 | 70 | 89 | 78 | 80 | 84 | 90 | ||
| DLCO, % | 69 | 96 | 82 | 56 | 50 | 84 | 82 | ||
| DLCO/VA, % | 75 | 93 | 82 | 61 | 74 | 82 | 82 | ||
Changes in lung volume and diffusing capacity and subjective health condition scores over time.
| pulmonary function test | time | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | Case 7 |
|---|---|---|---|---|---|---|---|---|
| FVC, % | 0 M | 89 | 101 | 104 | 110 | 91 | 92 | 87 |
| 3 M | 89 | 89 | 92 | 106 | 93 | 79 | ||
| 12 M | 105 | 78 | 82 | 97 | 95 | 71 | 82 | |
| 36 M | 97 | 66 | 89 | 78 | 75 | 73 | 82 | |
| FEV1, % | 0 M | 96 | 88 | 106 | 106 | 102 | 97 | 98 |
| 3 M | 97 | 88 | 96 | 103 | 105 | 90 | ||
| 12 M | 114 | 83 | 90 | 99 | 109 | 79 | 93 | |
| 36 M | 98 | 73 | 97 | 81 | 81 | 81 | 90 | |
| DLCO/VA, % | 0 M | 75 | 93 | 82 | 61 | 74 | 82 | 82 |
| 6 M | 110 | 97 | 115 | 84 | 98 | 97 | 101 | |
| 36 M | 109 | 96 | 116 | 90 | 97 | 108 | 109 | |
| Degree of subjective symptoms, % | 3 M | 50 | 40 | 50 | 60 | 60 | 60 | 60 |
| 12 M | 60 | 50 | 60 | 70 | 70 | 60 | 60 | |
| 36 M | 70 | 50 | 75 | 80 | 80 | 70 | 60 |